Clinical Correlates of Soluble sCD163 and IL9 in Patients with Chronic Kidney Disease and Lupus Nephritis | ||||
| Egyptian Journal of Medical Microbiology | ||||
| Article 21, Volume 34, Issue 2, April 2025, Page 183-187 PDF (197.44 K) | ||||
| Document Type: New and original researches in the field of Microbiology. | ||||
| DOI: 10.21608/ejmm.2025.346014.1406 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Ameer K. Mohammad; ِAhmed A.J. Aljanaby 
| ||||
| Department of Biology, Faculty of Science, University of Kufa, Iraq | ||||
| Abstract | ||||
| Background: Chronic kidney disease is a progressive condition characterized by the gradual deterioration of renal function, leading to the accumulation of waste products in the body. This condition affects over 800 million individuals globally with a disproportionate burden on older adults, women, racial minorities, and individuals with diabetes mellitus or hypertension. Objective: the aim of this works is to study the immunological role of cluster of differentiation163 and interleukin9 in patients with chronic kidney disease and lupus nephritis. Methodology: From 1st August 2023 until the end of January 2024, 40 healthy participants and 80 patients with chronic kidney disease and lupus nephritis were enrolled in this study at AL-Najaf Hospital. The ELISA test was used to test sCD163 and IL9 in each patients' blood. Results: Patients' serum levels of IL9 and sCD163 were substantially higher (P<0.05) than those of control participants. There was no appreciable variations in sCD163 and IL9 between cases with lupus nephritis and those with chronic renal disease. Conclusion: Our results proved that there was an important immunological role of sCD163 and IL9 in patients with chronic kidney disease and lupus nephritis. | ||||
| Keywords | ||||
| Biomarkers; Chronic kidney disease; Lupus nephritis; interleukins | ||||
|
Statistics Article View: 137 PDF Download: 40 |
||||
